Written question asked by Lord Tyrie (Non-affiliated) on Thursday, 9 June 2022, in the House of Lords. It was due for an answer on Thursday, 23 June 2022. It was answered by Lord Kamall (Conservative) on Thursday, 23 June 2022 on behalf of the Department of Health and Social Care.
Tixagevimab/cilgavimab
- Question
-
To ask Her Majesty's Government, further to the Written Answer by the Parliamentary Under Secretary of State for the Department of Health and Social Care on 7 June (1507), when they expect the UK Health Security Agency (UKHSA) testing review of Evusheld to be completed.
- Answer
-
AstraZeneca commissioned the UK Health Strategic Authority (UKHSA) to complete testing into the effectiveness of Evusheld against the Omicron variants. The initial testing is now complete and data has been shared with AstraZeneca. After reviewing the data, it is a matter for AstraZeneca to determine whether to commission further testing, therefore we are unable to confirm when testing will be completed.
Secondary information
- Type
- Written question
- Reference
- HL844
- Session
- 2022-23
- Related items
- Subjects
- Testing Immunosuppression Tixagevimab/cilgavimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-24 10:08:45 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL844
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL844
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL844